LAS VEGAS, NV - 
(NewMediaWire) - January 25, 2024 - BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and distributor of
innovative, all-natural dietary supplements, announces the achievement of
multiple Equine Championship Titles attributed to the advanced proprietary supplements
sold by its subsidiary, Livestock Impact, Inc.
The highlight of the 2023 season was the spectacular performance of Cheyanne
Colclasure with her 23 year old horse, Docs
Dual Quixote, who secured the 35,000 Non Pro National Championship Title at the
2023 United States Cutting Horse Association (USCHA) National Championship
annual competition in November. Notably, in 2023, Docs Dual Quixote, and
multiple other horses maintained on Livestock Impact supplements have become
National Champions, Reserve Champions and Top 5 members of various competitive classes.
Livestock Impact All-In-One supplement formulas for animals have been developed during the last five years to generally foster overall health and to specifically increase, speed, performance, resiliency, and endurance in equine. According to many observers, horses and dogs maintained on the All-In-One products display certain rejuvenating effects such as improved energy, agility, responsiveness. and reaction time.
Denise Colclasure, exclusive distributor for Livestock Impact, Inc., comments, “ We routinely see older horses, like Docs Dual Quixote (23), that are well beyond the average competition retirement age, standing in the Winner’s Circle because they are maintained on the popular Livestock Impact All-In-One products. To my knowledge, there are no other supplement formulas for animals with these rejuvenating effects.”
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
